Table 4.

Association between vena cava filter use and cancer site (N=13,104)

Cancer site	Total N	% using VCF	aOR^a	95% CI
Oral	146	8.2%	0.67	0.35	1.30
Skin	180	13.9%	1.06	0.66	1.73
Bone/soft tissue	167	11.4%	0.90	0.52	1.56
Stomach/small intestine	313	16.3%	1.17	0.80	1.70
Colorectal	1,392	16.2%	1.25	0.99	1.57
Liver	217	9.2%	0.85	0.50	1.45
Pancreas	796	11.2%	0.76	0.57	1.03
Lung/larynx/pleura	3,931	11.4%	1.02	0.83	1.25
Breast	776	7.6%	0.65	0.47	0.91
Uterus	312	15.1%	1.02	0.69	1.49
Cervix	165	17.0%	1.37	0.84	2.22
Ovarian	468	14.7%	1.13	0.81	1.58
Prostate	613	14.2%	0.98	0.72	1.32
Testicular	61	13.1%	1.62	0.66	3.95
Bladder	360	15.6%	1.12	0.79	1.58
Kidney	476	11.3%	1.09	0.76	1.55
Brain	308	24.4%	2.31	1.65	3.23
Thyroid	44	18.2%	1.22	0.46	3.24
Myeloma	378	12.2%	0.96	0.66	1.39
Leukemia	766	7.0%	0.64	0.46	0.90
Lymphoma	293	7.2%	0.76	0.46	1.26
Endocrine	121	14.0%	0.92	0.31	2.75
Metastatic	7,046	13.6%	1.13	1.00	1.29

Cancer-specific regression model included all covariates from the primary model. Results for those variables were not meaningfully different and are excluded here for brevity.

Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava filter